stockrow
Saturday 7 November 2026
Export GALT’s income statement to Excel — free account
Galectin Therapeutics Inc.
GALT Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- +63.1%
- Total debt
- −13.1%
Quarter to June 2026, against a year earlier
3.14
0.15
+5.02%
Follow GALT
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 180 | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (21) | (16) | (14) | (13) | (23) | (31) | (39) | (41) | (47) | (31) | (28) | +4.1% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (21) | (16) | (14) | (13) | (23) | (31) | (39) | (41) | (47) | (31) | (28) | +4.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.76) | (0.49) | (0.38) | (0.39) | (0.41) | (0.52) | (0.65) | (0.74) | (0.76) | (0.48) | (0.43) | (5.0%) | ||||||
| Cash flow | (0.56) | (0.45) | (0.26) | (0.21) | (0.36) | (0.42) | (0.52) | (0.55) | (0.67) | (0.37) | (0.24) | (4.4%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.56) | (0.45) | (0.26) | (0.21) | (0.36) | (0.42) | (0.52) | (0.55) | (0.67) | (0.37) | (0.24) | (4.4%) | ||||||
| Book value | 0.41 | 0.03 | 0.18 | 0.87 | 0.42 | 0.04 | (0.54) | (1.00) | (1.65) | (1.97) | (2.08) | n/m | ||||||
| Shares, m | 29 | 36 | 39 | 52 | 57 | 59 | 59 | 60 | 62 | 64 | 65 | +9.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (16) | (16) | (10) | (11) | (21) | (24) | (31) | (33) | (42) | (24) | (16) | +4.3% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Free cash flow | (16) | (16) | (10) | (11) | (21) | (24) | (31) | (33) | (42) | (24) | (16) | +4.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 12 | 1 | 7 | 45 | 24 | 33 | 8 | 12 | (18) | 11 | (137) | (0.6%) | |||||
| Net debt | (15) | (3) | (8) | (47) | (27) | (11) | 21 | 46 | 70 | 116 | 91 | n/m | ||||||
| Shareholders’ equity | 12 | 1 | 7 | 46 | 24 | 3 | (32) | (60) | (103) | (126) | (137) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (105.92) | (175.06) | (228.56) | (70.22) | (60.47) | (85.96) | (123.19) | (181.09) | (206.59) | (167.30) | (184.22) | (61.4) pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (217.67) | 740.75 | 306.67 | (97.74) | (72.31) | (275.21) | 228.26 | 92.49 | 56.27 | 26.51 | 21.69 | +244.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 7 | 7 | 6 | 7 | 6 | 9 | 12 | 14 | 15 | 9 | — | +2.8% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Galectin Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| EIKN Eikon Therapeutics, Inc. | $316.3M | — (loss-making) | — | — | n/m | +15.18% (above 0%: growing) | — | 0.00% | Compare |
| ALEC Alector, Inc. | $309.9M | 6.6× | — (loss-making) | +4,895.89% (above 0%: growing) | n/m | +25.73% (above 0%: growing) | 100.00% | 76.04% | Compare |
| XFOR X4 Pharmaceuticals, Inc. | $304.4M | — (loss-making) | — (loss-making) | +63.12% (above 0%: growing) | n/m | +27.45% (above 0%: growing) | 82.18% | (694.37%) | Compare |
| BNTC Benitec Biopharma Limited | $301.5M | — (loss-making) | — (loss-making) | −85.42% (below 0%: shrinking) | n/m | +38.90% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GALT Galectin Therapeutics Inc. | $301.0M | — (loss-making) | — | — | n/m | +63.06% (above 0%: growing) | 0.00% | 0.00% | |
| ENTA Enanta Pharmaceuticals, Inc. | $293.6M | — (loss-making) | — (loss-making) | −21.60% (below 0%: shrinking) | n/m | −157.51% (below 0%: shrinking) | 100.00% | (120.04%) | Compare |
| SCTX Scribe Therapeutics Inc. | $293.1M | — | — | — | n/m | — | 100.00% | (489.83%) | Compare |
| AGEN Agenus Inc. | $290.8M | 10.7× | 27.7× | +4.14% (above 0%: growing) | −99.00% (below 0%: shrinking) | −37.06% (below 0%: shrinking) | 100.00% | 36.23% | Compare |
| KYTX Kyverna Therapeutics, Inc. | $285.1M | — (loss-making) | — (loss-making) | — | n/m | −27.06% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $297.5M | — | — | +4.14% | — | +15.18% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 13 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.17m | 1.69m | 322.48 |
| 2024 | 1.19m | 1.05m | 77.71 |
| 2023 | 963.65k | 1.06m | 146.90 |
Ownership
Directors and executive officers, together
4.10%
Richard E. Uihlein
49.40%
David Smith
14.50%
Early Equities LLC
8.39%
James C. Czirr
8.30%
10X Fund, L.P.
5.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement